Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 1, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new device called the Nanodropper, which is designed to deliver smaller eye drops for patients with glaucoma. Glaucoma is a serious eye condition that can lead to blindness if not treated properly. The trial aims to see if using the Nanodropper can effectively lower the pressure inside the eye, just like the standard larger eye drops that many patients currently use.

To participate in the trial, you need to be at least 18 years old and have a diagnosis of open-angle glaucoma or ocular hypertension. You should also be using a specific type of eye drop called a prostaglandin analogue and have stable eye health over the last six months. If you join, you can expect to use the Nanodropper and help researchers learn more about its effectiveness. The trial is open to all genders and is currently looking for volunteers. This is an important study that could potentially improve treatment options for people with glaucoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years old or older
• • 2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
• • 3. Use of prostaglandin analogue (PGA) eye drop
• • 4. Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)
• Exclusion Criteria:
• • 1. Uncontrolled glaucoma
• • 2. Have had eye surgery (including laser procedures) within the past six months
• • 3. Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
• • 4. Use of non-PGA class of IOP-lowering medication